Huntington's disease (HD) symptoms are driven to a large extent by dysfunction of the basal ganglia circuitry. HD patients exhibit reduced striatal phoshodiesterase 10 (PDE10) levels. Using HD mouse models that exhibit reduced PDE10, we demonstrate the benefit of pharmacologic PDE10 inhibition to acutely correct basal ganglia circuitry deficits. PDE10 inhibition restored corticostriatal input and boosted cortically driven indirect pathway activity. Cyclic nucleotide signaling is impaired in HD models, and PDE10 loss may represent a homeostatic adaptation to maintain signaling. Elevation of both cAMP and cGMP by PDE10 inhibition was required for rescue. Phosphoproteomic profiling of striatum in response to PDE10 inhibition highlighted plausible neural substrates responsible for the improvement. Early chronic PDE10 inhibition in Q175 mice showed improvements beyond those seen with acute administration after symptom onset, including partial reversal of striatal deregulated transcripts and the prevention of the emergence of HD neurophysiological deficits. VIDEO ABSTRACT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neuron.2016.10.064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Novel PDE10A Inhibitor for Tourette Syndrome and Other Movement Disorders.
Cells
July 2024
EuMentis Therapeutics Inc., 275 Grove Street, 2-400, Newton, MA 02466, USA.
Article Synopsis
- Tourette syndrome is a movement disorder linked to basal ganglia dysfunction, and PDE10A inhibitors, like EM-221, may help treat it.
- EM-221 effectively inhibited PDE10A in lab tests and showed promise in reducing hyperactivity and other behavioral issues in rats, with good safety profiles in both rats and dogs.
- The study supports moving forward with phase 2 trials for EM-221 in humans with Tourette syndrome and related disorders, as it demonstrated high enzyme occupancy and tolerability.
[Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure].
Med Sci (Paris)
July 2024
Université Paris-Saclay, Inserm UMR-S 1180, Orsay, France.
Cyclic nucleotide phosphodiesterases (PDEs) modulate neurohormonal regulation of cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple isoforms of PDEs with different enzymatic properties and subcellular locally regulate cyclic nucleotide levels and associated cellular functions. This organisation is severely disrupted during hypertrophy and heart failure (HF), which may contribute to disease progression.
View Article and Find Full Text PDFNovel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats.
Cancers (Basel)
January 2023
Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
The nonsteroidal anti-inflammatory drug (NSAID) sulindac demonstrates attractive anticancer activity, but the toxicity resulting from cyclooxygenase (COX) inhibition and the suppression of physiologically important prostaglandins precludes its long-term, high dose use in the clinic for cancer prevention or treatment. While inflammation is a known tumorigenic driver, evidence suggests that sulindac's antineoplastic activity is partially or fully independent of its COX inhibitory activity. One COX-independent target proposed for sulindac is cyclic guanosine monophosphate phosphodiesterase (cGMP PDE) isozymes.
View Article and Find Full Text PDFThe Antidepressant-like Activity, Effects on Recognition Memory Deficits, Bioavailability, and Safety after Chronic Administration of New Dual-Acting Small Compounds Targeting Neuropsychiatric Symptoms in Dementia.
Int J Mol Sci
September 2022
Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland.
This study aimed to extend the body of preclinical research on prototype dual-acting compounds combining the pharmacophores relevant for inhibiting cyclic nucleotide phosphodiesterase 10 (PDE10A) and serotonin 5-HT/5-HT receptor (5-HTR/5-HTR) activity into a single chemical entity (compounds PQA-AZ4 and PQA-AZ6). After i.v.
View Article and Find Full Text PDFCyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.
Nat Rev Cardiol
February 2023
Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France.
Cyclic nucleotide phosphodiesterases (PDEs) modulate the neurohormonal regulation of cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes with different enzymatic properties and subcellular localization regulate local pools of cyclic nucleotides and specific functions. This organization is heavily perturbed during cardiac hypertrophy and heart failure (HF), which can contribute to disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!